EDGEWISE THERAPEUTICS INC (EWTX)
Sector: Health Care
2026 Annual Meeting Analysis
EDGEWISE THERAPEUTICS INC · Meeting: June 4, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors to serve until the 2029 Annual Meeting of Stockholders
Brege has served since December 2020 (over 5 years), bringing extensive biotech finance and operating experience; EWTX's 3-year return of +372.5% far exceeds the peer group median of +72.6% by +299.9 percentage points, well above the 50pp underperformance threshold needed to trigger a against vote, and she meets attendance requirements with no overboarding concerns.
Edris has served since February 2021 as a co-founder with deep biotech operating and venture experience; the TSR trigger does not apply given EWTX's exceptional 3-year outperformance of peers by +299.9 percentage points, and there are no attendance, overboarding, or independence concerns.
Root has served since August 2019 with relevant medical and venture capital experience; EWTX's strong 3-year outperformance of the peer group by +299.9 percentage points means the TSR trigger does not apply, and Root chairs the Nominating & Corporate Governance Committee with no attendance or overboarding issues identified.
All three Class II director nominees — Brege, Edris, and Root — are recommended FOR. EWTX's 3-year stock return of +372.5% outperforms the compensation peer group median by +299.9 percentage points, far exceeding the 50pp threshold required to trigger an against vote for strong-positive-TSR companies, so no TSR-related concerns arise. No overboarding, attendance, independence, or qualifications red flags were identified for any nominee.
Say on Pay
✓ FORCEO
Kevin Koch, Ph.D.
Total Comp
$7,359,546
Prior Support
N/A
CEO Kevin Koch's total compensation of $7,359,546 for 2025 is reasonable for a late-stage biotech CEO at a $3.4 billion company, with the majority of pay delivered through stock options and restricted stock units (equity awards totaling approximately $6.2 million, or roughly 85% of total pay), well above the 50-60% variable-pay threshold the policy requires. The company's stock has returned +372.5% over three years versus a peer group median of +72.6%, meaning the above-benchmark incentive pay is strongly justified by shareholder outcomes — executives and shareholders prospered together. The company has a clawback policy adopted in October 2023 in compliance with SEC and Nasdaq requirements, no prior Say on Pay vote history exists to evaluate (this is identified as a new annual vote starting this year), and no red flags were found in pay mix, dilution levels, or compensation structure.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
6 yrs
Audit Fees
$770,000
Non-Audit Fees
$0
KPMG LLP has served as EWTX's auditor since 2020 (approximately 6 years), well below the 25-year tenure threshold that would raise independence concerns. In 2025, non-audit fees were zero — the entire $770,000 billed consisted of core audit fees — so there is no independence concern from non-audit work. KPMG is a Big 4 firm appropriate for a $3.4 billion market-cap company, and no material financial restatements were disclosed.
Overall Assessment
Edgewise Therapeutics' 2026 annual meeting presents a clean ballot with no contentious proposals: all three director nominees are well-qualified incumbents with strong tenure and no governance concerns, KPMG has audited the company cleanly with zero non-audit fees, and the executive compensation program is well-structured with heavily equity-weighted pay that has clearly tracked exceptional shareholder returns over the past three years. All three proposals are recommended FOR with no material policy triggers firing.
Compensation Peer Group
26 companies disclosed in 2026 proxy filing